Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity - PubMed (original) (raw)

Comment

Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity

J W Young et al. J Exp Med. 1996.

No abstract available

PubMed Disclaimer

Comment on

• Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.
  Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Celluzzi CM, et al. J Exp Med. 1996 Jan 1;183(1):283-7. doi: 10.1084/jem.183.1.283. J Exp Med. 1996. PMID: 8551233 Free PMC article.
• Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
  Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Paglia P, et al. J Exp Med. 1996 Jan 1;183(1):317-22. doi: 10.1084/jem.183.1.317. J Exp Med. 1996. PMID: 8551239 Free PMC article.
• Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
  Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ. Zitvogel L, et al. J Exp Med. 1996 Jan 1;183(1):87-97. doi: 10.1084/jem.183.1.87. J Exp Med. 1996. PMID: 8551248 Free PMC article.

Similar articles

• Dendritic cells and interleukin 12 as adjuvants for tumor-specific vaccines.
  Grohmann U, Bianchi R, Belladonna ML, Silla S, Surace D, Fioretti MC, Puccetti P. Grohmann U, et al. Adv Exp Med Biol. 1997;417:579-82. doi: 10.1007/978-1-4757-9966-8_93. Adv Exp Med Biol. 1997. PMID: 9286421 No abstract available.
• Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy.
  Han HD, Byeon Y, Kang TH, Jung ID, Lee JW, Shin BC, Lee YJ, Sood AK, Park YM. Han HD, et al. Int J Nanomedicine. 2016 Nov 2;11:5729-5742. doi: 10.2147/IJN.S109001. eCollection 2016. Int J Nanomedicine. 2016. PMID: 27843314 Free PMC article.
• Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells.
  Rawson P, Hermans IF, Huck SP, Roberts JM, Pircher H, Ronchese F. Rawson P, et al. Cancer Res. 2000 Aug 15;60(16):4493-8. Cancer Res. 2000. PMID: 10969797
• gp96--the immune system's Swiss army knife.
  Schild H, Rammensee HG. Schild H, et al. Nat Immunol. 2000 Aug;1(2):100-1. doi: 10.1038/77770. Nat Immunol. 2000. PMID: 11248798 Review. No abstract available.
• [Antitumor cellular immunotherapy: the breakthrough of dendritic cells].
  Angevin E, André F, Zitvogel L. Angevin E, et al. Bull Cancer. 2000 Jan;87(1):107-15. Bull Cancer. 2000. PMID: 10673639 Review. French. No abstract available.

Cited by

• Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis.
  Seo N, Tokura Y, Nishijima T, Hashizume H, Furukawa F, Takigawa M. Seo N, et al. Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):371-6. doi: 10.1073/pnas.97.1.371. Proc Natl Acad Sci U S A. 2000. PMID: 10618425 Free PMC article.
• Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.
  Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ. Maraskovsky E, et al. J Exp Med. 1996 Nov 1;184(5):1953-62. doi: 10.1084/jem.184.5.1953. J Exp Med. 1996. PMID: 8920882 Free PMC article.
• Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue.
  Ludewig B, Odermatt B, Landmann S, Hengartner H, Zinkernagel RM. Ludewig B, et al. J Exp Med. 1998 Oct 19;188(8):1493-501. doi: 10.1084/jem.188.8.1493. J Exp Med. 1998. PMID: 9782126 Free PMC article.
• Tumor antigens discovery: perspectives for cancer therapy.
  Wang RF. Wang RF. Mol Med. 1997 Nov;3(11):716-31. Mol Med. 1997. PMID: 9407548 Free PMC article. Review.
• Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model.
  Jouanneau E, Poujol D, Gulia S, Le Mercier I, Blay JY, Belin MF, Puisieux I. Jouanneau E, et al. Cancer Immunol Immunother. 2006 Mar;55(3):254-67. doi: 10.1007/s00262-005-0040-7. Epub 2005 Aug 27. Cancer Immunol Immunother. 2006. PMID: 16133115 Free PMC article.

References

1. 1. Eur J Immunol. 1988 Feb;18(2):219-23 - PubMed
2. 1. J Exp Med. 1994 Apr 1;179(4):1109-18 - PubMed
3. 1. J Clin Invest. 1990 Mar;85(3):955-61 - PubMed
4. 1. J Exp Med. 1990 Apr 1;171(4):1315-32 - PubMed
5. 1. J Exp Med. 1990 Aug 1;172(2):631-40 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database